Search Results - Oleg Schmidt‐Kittler
- Showing 1 - 14 results of 14
-
1
-
2
SCOMP Is Superior to Degenerated Oligonucleotide Primed-Polymerase Chain Reaction for Global Amplification of Minute Amounts of DNA from Microdissected Archival Tissue Samples by Nikolas H. Stoecklein, Andreas Erbersdobler, Oleg Schmidt‐Kittler, Joachim Diebold, Julian Schardt, Jakob R. Izbicki, Christoph A. Klein
Published 2002Artigo -
3
-
4
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations by Genglin Jin, Zachary J. Reitman, Ivan Spasojević, Ines Batinić‐Haberle, Jian Yang, Oleg Schmidt‐Kittler, Darell D. Bigner, Hai Yan
Published 2011Artigo -
5
Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer by Julian Schardt, Manfred Meyer, Claudia Hartmann, Falk Schubert, Oleg Schmidt‐Kittler, Christine Fuhrmann, Bernhard Polzer, Marco Petronio, Roland Eils, Christoph A. Klein
Published 2005Artigo -
6
-
7
Mutant PIK3CA promotes cell growth and invasion of human cancer cells by Yardena Samuels, Luis A. Díaz, Oleg Schmidt‐Kittler, Jordan M. Cummins, Laura J. DeLong, Ian Cheong, Carlo Rago, David L. Huso, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu
Published 2005Artigo -
8
Structural basis of nSH2 regulation and lipid binding in PI3Kα by Michelle S. Miller, Oleg Schmidt‐Kittler, David M. Bolduc, Evan T. Brower, Daniele Chaves‐Moreira, Marc Allaire, Kenneth W. Kinzler, Ian G. Jennings, Philip E. Thompson, Philip A. Cole, L. Mario Amzel, Bert Vogelstein, Sandra B. Gabelli
Published 2014Artigo -
9
From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression by Oleg Schmidt‐Kittler, Thomas Ragg, Angela Daskalakis, Martin Granzow, A. Ahr, Thomas Blankenstein, Manfred Kaufmann, Joachim Diebold, H Arnholdt, Peter E. Müller, Joachim Bischoff, Detlev Harich, Günter Schlimok, Gert Riethmüller, Roland Eils, Christoph A. Klein
Published 2003Artigo -
10
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain by Susanne Grünewald, Lillian R. Klug, Thomas Mühlenberg, Jonas Lategahn, Johanna Falkenhorst, Ajia Town, Christiane Ehrt, Eva Wardelmann, Wolfgang Hartmann, Hans‐Ulrich Schildhaus, Juergen Treckmann, Jonathan A. Fletcher, Sascha Jung, Paul Czodrowski, Steven P. Miller, Oleg Schmidt-Kittler, Daniel Rauh, Michael C. Heinrich, Sebastian Bauer
Published 2020Carta -
11
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial by Daniel J. DeAngelo, Deepti Radia, Tracy I. George, William A. Robinson, Albert Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans‐Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica Evans, Huimin Lin, Brenton G. Mar, Srđan Verstovšek, Michael W. Deininger, Jason Gotlib
Published 2021Artigo -
12
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations by Erica Evans, Alexandra K. Gardino, Joseph L. Kim, Brian L. Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson, Lucian DiPietro, Yulian Zhang, Natasja Brooijmans, Timothy P. LaBranche, Agnieszka Woźniak, Yemarshet K. Gebreyohannes, Patrick Schöffski, Michael C. Heinrich, Daniel J. DeAngelo, Steven P. Miller, Beni B. Wolf, Nancy E. Kohl, Timothy J. Guzi, NICHOLAS B. LYDON, Andy Boral, Christoph Lengauer
Published 2017Artigo -
13
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across<i>FGFR2</i>Alterations and Resistance Mutations by Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B. Barry Touré, Songping Zhao, Roberto Valverde, Patrick J. O’Hearn, Demetri T. Moustakas, Heike Schönherr, Nastaran Gerami-Moayed, Alexander M. Taylor, Brandi M. Hudson, Damian J. Houde, Debjani Pal, Lindsey Foster, Hakan Günaydin, Pelin Ayaz, Dina A. Sharon, Lipika Goyal, Alison M. Schram, Suneel Kamath, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Kai Yu Jen, Fabien Ricard, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, Jessica B. Casaletto
Published 2023Artigo -
14
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma by Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang
Published 2019Artigo
Search Tools:
Related Subjects
Biology
Gene
Genetics
Cancer research
Medicine
Cancer
Mutation
Mutant
Biochemistry
Comparative genomic hybridization
Cell biology
Genome
Immunology
Internal medicine
Molecular biology
Pathology
Adverse effect
Allele
Bone marrow
Breast cancer
Cancer cell
Chemistry
Computational biology
DNA
DNA extraction
Enzyme
Gastroenterology
GiST
Loss of heterozygosity
Metastasis